An unexpected health scare motivated me to start my own company, which I eventually sold to Boston Scientific for $275 million.

The decision to reject the offer was stressful, as many believed we should sell the company, and I realized I hadn't effectively communicated our mission to the team. Turning down Yahoo's billion dollar offer was painful because it led to a significant loss of trust within the company, resulting in many employees leaving due to a lack of belief in our vision.

Signing the acquisition deal felt surreal, especially with my family by my side, marking a significant moment in my journey and securing the future of our product in women's health.

After selling my company, I was invited to be the first healthcare and biotech partner at Y Combinator, where I could share my story and help other founders.

I was a happy surgeon, but after a two-year break in Boston working at Dana Farber Cancer Institute, I realized entrepreneurship looked really appealing.

When we announced the acquisition, I was worried the team would be upset, but instead, they cheered, which was a beautiful moment for me as a founder.

Since turning down the offer, I've faced much harder decisions that required betting on the company's direction or investing billions, where the outcomes weren't clear for many years.

After raising our seed round, we went on to raise about $20 million more in venture capital, taking our device through prototype stages and clinical studies, ultimately achieving FDA clearance.

I turned down a $12 billion offer from Microsoft because I felt that we had a unique opportunity to create something special and control our own destiny.